Chargement en cours...
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
Immunotherapy has revolutionized the management of metastatic renal cell carcinoma with four checkpoint inhibitors (nivolumab, ipilimumab, avelumab, and pembrolizumab) approved either as monotherapy or as combination therapy. The use of ipilimumab and nivolumab for treatment-naïve, intermediate to p...
Enregistré dans:
| Publié dans: | Cancer Manag Res |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7320748/ https://ncbi.nlm.nih.gov/pubmed/32606975 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S202017 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|